DNA Script, a Paris, France-based Synthetic DNA manufacturer, raised €11m ($13m) in Series A funding.
The round was led by Illumina Ventures, with participation from Merck Ventures BV, the corporate venture arm of Merck KGaA, and existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners. In conjunction with the funding, Nick Naclerio, Founding Partner of Illumina Ventures, joined DNA Script’s board.
The company intends to use the funds to strengthen its enzymatic technology and nucleotide chemistry platform in order to manufacture oligonucleotides faster and affordably.
Founded in 2014 by Thomas Ybert, PhD, CEO, DNA Script manufactures de novo synthetic nucleic acids using an enzymatic technology. The company aims to introduce a novel biochemical process for DNA and RNA synthesis based on the use of efficient enzymes. This technology mimics the way nature produces genetic code and enables enhanced performance while minimizing the use of harsh chemicals.